Bracket Global, a provider of clinical research solutions, and Clintara, a privately held clinical service and technology company headquartered in Boston, Mass., have agreed to combine. Bracket will integrate the Clintara platform of surveillance strategies developed for clinical trials within Bracket's proprietary electronic platform for Clinical Outcome Assessments (eCOA). The integration will include Clintara's innovative C-VISA Subject Eligibility Validation program designed to ensure appropriate patients are enrolled in clinical trials.
Founded in 2009 by Steven D. Targum, M.D., Clintara's methodology and technology includes audio-digital pen recordings of site-based interviews and site-independent "dual" scoring reviews. The Clintara surveillance strategy has enhanced ratings precision and improved the data integrity of clinical trials.
The Clintara leadership will assume expanded roles within Bracket. Targum will become the scientific director of Bracket and will work closely with Bracket's senior vice president and chief medical officer, David Daniel, M.D. Clintara CEO Colin Bower will become vice president, scientific services and will work with the Bracket leadership team and scientific advisory board to develop solutions to improve the conduct of clinical trials.